Hector Chinoy, Robert G. Cooper
Oxford University Press, Jan 4, 2018 - Myositis - 192 pages
The idiopathic inflammatory myopathies (IIM) are a rare group of autoimmune diseases, negatively affecting the lives of an estimated 250,000 people worldwide. Delays in diagnosis often occur owing to a lack of recognition of disease presentation, or misdiagnosis, both of which can lead to muscle atrophy.
This new addition to the Oxford Rheumatology Library series focuses on providing a summary of what is currently understood about the epidemiology of myositis, controversies in diagnosis criteria, clinical features, and the current paradigms for treatment and intervention. Designed to bring together the multi-disciplinary involvement of healthcare professionals for IMM patients, this is the first easy-to-navigate guide for the practical management of myositis.
This is an essential guide for both physicians and trainees in Rheumatology, Neurology, and Dermatology specialities.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
abnormalities acid adult and juvenile antibodies antigens assessment associated atrophy autoantibodies autoimmune myopathy Bohan cancer cardiac cause cells chronic ciclosporin CK levels classification criteria Clin clinical features contractures creatine kinase diagnosis disease activity disorders distal drugs dysphagia Electromyography elevated CK evaluation fatty flexor gene glucocorticoids hyperCKaemia idiopathic inflammatory myopathies IIM patients immune immunosuppressive IMNM inclusion body myositis increased inflammation interstitial lung disease involvement IVIGs juvenile dermatomyositis magnetic resonance malignancy McArdle disease metabolic myopathies methotrexate mitochondrial motor units MUAP muscle biopsy muscle disease muscle enzymes muscle fibres muscle oedema muscle strength muscle symptoms muscle weakness muscular dystrophy mutations myalgia myositis-specific necrotizing myopathy Nerve Neurol neuromuscular normal onset patients with IIM patients with myositis perifascicular phenotype polymyositis Pompe disease potential present protein response rhabdomyolysis Rheumatol Rheumatology risk rituximab serum sIBM skeletal muscle skin specific sporadic inclusion body statin syndrome therapy treatment trials